Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

NJ Policy Perspective

NJPP Study: 500K New Jersey Residents Would Lose Insurance Under GOP Healthcare Plan

Trenton, NJ, March 22, 2017 — Jonathan D. Salant reports in The Star-Ledger/NJ.com that U.S. House Republican legislation to repeal and replace the Affordable Care Act would leave 500,000 more New Jersey residents without health insurance, according to a study released by New Jersey Policy Perspective (NJPP) just two days before lawmakers will be asked to vote on the bill.

Study highlights include:

  • Half a million New Jersey residents would lose health coverage;
  • 250 millionaires in the state are set to receive a total $14 million tax break;
  • The hardest-hit would be the 45 and older population and Medicaid populations — both of which are the largest enrolled groups.

Continue reading

New Jersey Policy Perspective Reports: An Obamacare Repeal Without Replacement Will ‘Devastate’ the Garden State

Trenton, NJ, February 22, 2017 — According to a new report from the New Jersey Policy Perspective, if Congress repeals the Affordable Care Act (ACA) — well known as Obamacare — and doesn’t replace it, the loss of coverage for an estimated 800,000 New Jersey residents would be only part of the story, reports Lindy Washburn in The Record/NorthJersey.com.

The report presents county-by-county data about the effect of ACA repeal.

In addition, Livio reports that more than 210,000 seniors who rely on Medicare and have substantial prescription drug needs would face higher out-of-pocket costs. Continue reading